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Background: Hepatitis C virus (HCV) infection is a major preventable and treatable cause of morbidity and
mortality. The ability to link population based centralized laboratory HCV testing data with administrative databases
provided a unique opportunity to compare mortality between HCV seronegative and seropositive individuals.
Through the use of laboratory testing patterns and results, the objective of this study was to differentiate the viral
effects of mortality due to HCV infection from risk behaviours/activities that are associated with acquisition of HCV
infection.
Methods: Serological testing data from the British Columbia (BC) Centre for Disease Control Public Health
Microbiology and Reference Laboratory from 1992–2004 were linked to the BC Vital Statistics Agency death registry.
Four groups of HCV testers were defined by their HCV antibody (anti-HCV) testing patterns: single non-reactive
(SNR); serial multiple tested non-reactive (MNR); reactive at initial testing (REAC); and seroconverter (SERO)
(previously seronegative followed by reactive, a marker for incident infection). Standardized mortality ratios (SMRs)
were calculated to compare the relative risk of all cause and disease specific mortality to that of the BC population
for each serological group. Time dependent Cox proportional hazard regression was used to compare hazard ratios
(HRs) among HCV serological groups.
Results: All anti-HCV testers had higher SMRs than the BC population. Referent to the SNR group, the REAC group
had higher risks for liver (HR: 9.62; 95% CI=8.55-10.87) and drug related mortality (HR: 13.70; 95% CI=11.76-16.13).
Compared to the REAC group, the SERO group had a lower risk for liver (HR: 0.53; 95% CI=0.24-0.99), but a higher
risk for drug related mortality (HR: 1.54; 95% CI=1.12-2.05).
Conclusions: These findings confirm that individuals who test anti-HCV positive have increased mortality related to
progressive liver disease, and that a substantial proportion of the mortality is attributable to drug use and risk
behaviours/activities associated with HCV acquisition. Mortality reduction in HCV infected individuals will require
comprehensive prevention programming to reduce the harms due to behaviours/activities which relate to HCV
acquisition, as well as HCV treatment to prevent progression of chronic liver disease.
Keywords: Hepatitis C virus, Mortality, Chronic hepatitis, Injection drug use, Data linkageBackground
Hepatitis C virus (HCV) infection is associated with sig-
nificant morbidity and mortality. World-wide, appro-
ximately 170 million people are infected with HCV,
including 243,000 to 300,000 Canadians and 60,000 British
Columbians [1-3]. About 25% of infected individuals* Correspondence: mel.krajden@bccdc.ca
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reproduction in any medium, provided the orspontaneously clear infection and 75% become chronically
infected [4,5]. Within 20 to 30 years of infection, approxi-
mately 10% to 40% of HCV-infected individuals will de-
velop cirrhosis [6], and about 1% to 5% will develop
hepatocellular carcinoma [7]. End stage liver disease
caused by HCV infection is the primary reason for liver
transplantation in Western Europe and North America
[8-11]. Most new HCV infections occur in people who
inject drugs (IDU) [1], whose risk activities may result in
mortality unrelated to HCV infection, and for this popula-
tion, the risk of death from drug related causes is greaterThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Study population. PHN, personal health number; MoH,
Ministry of Health.
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been shown to significantly reduce morbidity and mortal-
ity [16-18]. Approximately 50% of individuals who are able
to tolerate interferon/ribavirin therapies achieve sustained
virological response. The addition of protease inhibitors
improves curability to about 65% to 75% and the large
number of antiviral agents in the therapeutic pipeline will
likely result in cure rates of greater than 90% [18].
We examined the HCV-attributable disease burden by
estimating all cause and disease specific mortality among
individuals who underwent HCV serological testing be-
tween 1992 and 2004 in British Columbia (BC), Canada.
We also differentiated mortality due to HCV infection
from risk activities associated with HCV acquisition.
Methods
Study design
The study is a retrospective cohort study that involves se-
condary data analysis based on linked administrative data-
bases. A cohort of individuals who underwent serological
testing for anti-HCV from April 1992 to July 2004 at the
BC Centre for Disease Control (BCCDC) Public Health
Microbiology and Reference Laboratory were linked to
the BC Vital Statistics Agency death registry and the BC
Ministry of Health (MoH) Registration & Premium Billing
files. The exposure variable, the HCV serological group,
was defined based on anti-HCV testing patterns and re-
sults. The outcome variables, survival time and underlying
cause of death, were obtained from the linked death cer-
tificate data.
Study population
To be eligible for the study, individuals had to have at least
one anti-HCV test between 1992 and 2004 and a valid
personal health number (PHN), which is available to any-
one who has resided in BC for at least three months and
indicates insurance coverage under the BC population
Medical Services Plan (MSP). The HCV test dataset con-
tained a total of 593,033 individuals (Figure 1). Unique
individuals with a PHN were sent for matching to the BC
MoH Client Registry System, the central demographics
file for BC residents insured by MSP. Data quality exclu-
sions included situations such as the first available test
date was after the date of death or before the date of birth;
the date of last registration with MSP was before the test
date; the individual was less than one year of age and
HCV antibodies may have been maternally acquired; or
the individual was more than 100 years of age (n=6), as
there were concerns about errors in dates. In order to
limit the impact of notification bias from individuals with
co-morbid illnesses being tested more often, and persons
who died being more likely to have been hospitalized and
tested for HCV, the start date for entry to each HCV sero-
logical group was delayed for twelve months, i.e., 12-month lagging [19,20]. A total of 370,137 individuals who
had at least one anti-HCV test from 1992 to 2004 and
remained alive for at least twelve months after their first
anti-HCV test were eligible for analysis (Figure 1).
The observation period was the date an individual en-
tered a serological group until: 1) they became part of a
different group; 2) they ceased to be registered with MSP;
3) they died; or 4) the study period ended. Individuals who
ceased to be registered (usually as a result of leaving the
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study period were censored at the date of last registration.
Data sources
The HCV test dataset included all anti-HCV tests per-
formed between April 1992 and July 2004 at the BCCDC
Public Health Microbiology and Reference Laboratory,
which performs about 95% of anti-HCV testing in BC
[21]. HCV testing data were deterministically linked with
the MoH administrative databases by Population Data BC,
which houses longitudinal person-specific health data on
BC residents [22]. The MSP Registration & Premium
Billing files were used to determine subject age and sex
and date of last registration. All deaths of BC residents
registered in the province are captured in the death regis-
try maintained by the BC Vital Statistics Agency. Date of
death was used to determine survival time for time to
event analysis. Underlying causes of death were coded
according to the tenth edition of the International Classifi-
cation of Diseases (ICD-10). All personally identifiable in-
formation was removed from the linked dataset prior to
analysis.
Time dependent HCV serological groups
In order to best represent changes in HCV serological
status over time, four time dependent HCV serological
groups were defined: 1) single non-reactive (SNR), be-
ginning at the first non-reactive anti-HCV test and end-
ing when a second test was identified; 2) multiple tested
non-reactive (MNR), beginning at the second non-
reactive test and continuing until a reactive result was
identified; 3) anti-HCV reactive at initial testing (REAC)
and 4) seroconverter (SERO), beginning when an indi-
vidual had a reactive result preceded by one or more
non-reactive results. No time limit was applied between
test dates for defining the MNR and SERO groups, ex-
cept that the tests had to occur between 1992 and 2004,
and had to meet the 12-month lagging period from the
first test. The median time between the last negative and
first positive tests for the SERO group was 74 weeks
(interquartile range; 33, 153). These testing patterns and
results were also used as indicators of risk. The SNR
group may have had a risk such as history of transfusion
prior to screening the blood supply, or they may have
been tested for diagnostic work-up or insurance pur-
poses. However, since they had no subsequent tests, they
probably had few, if any, ongoing risks. Because of the
multiple testing, the MNR group likely had ongoing
risks such as IDU or renal dialysis. The REAC group
may have been tested because of symptoms of liver dis-
ease, or because of risk factors, and likely includes most
chronic HCV cases. The SERO group likely had current
or ongoing risks, typically IDU. Serological group classi-
fication was time dependent and individuals could fallinto more than one group, e.g., individuals who had
multiple non-reactive anti-HCV results would be in the
SNR group at the time of their first test and in the MNR
group for their subsequent tests. When a reactive test
result occurred, they would become part of the SERO
group.
Statistical methods
Standardized mortality ratios (SMR), observed deaths di-
vided by expected deaths, were calculated to compare all
cause and disease specific mortality for each serological
group with the BC population; 95% confidence intervals
were calculated by Byar’s approximation [23]. Observed
deaths were obtained by sex and year by summarizing
the number of deaths for each five year age group for
each serological group in the study cohort from 1992 to
2004. Expected deaths were obtained by multiplying the
calculated person years for each 5-year age stratum in
each serological group by the BC population death rate
for the respective 5-year age stratum. The same calcula-
tion was applied for each disease specific underlying
cause of death when calculating a disease specific SMR.
Since assignment of individuals to the HCV serological
groups may change over time, the time dependent Cox
proportional hazards model [24] was used to estimate
the hazard ratios (HR) for mortality between groups, ad-
justed for age and sex. Survival time was defined as the
time of the first group entry until the date of death or
last follow-up. Profile likelihood was used to calculate
95% confidence intervals [25]. HRs were calculated for:
1) MNR vs. SNR, to compare the ongoing risk group
(MNR) to the lowest risk group (SNR); 2) REAC vs.
SNR, to compare the group containing most chronic
infections to the lowest risk group; 3) SERO vs. SNR,
to compare seroconverters to the lowest risk group;
4) SERO vs. MNR, to compare seropositive to seronega-
tive individuals with ongoing risk; 5) SERO vs. REAC, to
compare mortality risk due to activities associated with
HCV acquisition vs. the risk resulting from chronic in-
fection. Due to the small number of observed deaths in
the SERO group, the REAC and SERO groups were
combined to form the HCV positive group for some
analyses. Time dependent Cox proportional hazards
models were fit to overall mortality and specific causes
of death a priori thought to be related to HCV. Models
were not applied for causes of death with five or fewer
observed deaths in the HCV positive group due to the
lack of statistical power. Schoenfeld residuals on func-
tions of time were plotted and examined for each cause
of death and for each group comparison [26]. With 12-
month lagging, no substantial departures from the pro-
portional hazards were observed.
Interactions between HCV serological groups and age
and sex were explored to determine if the age and sex
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If the interaction effects were statistically significant, we
rejected the hypothesis that the association (HR) did not
differ between strata and separate HRs were calculated
for each age group or sex, or both. All analyses were
performed with SAS Version 9.2 (Statistical Analysis
Software, Cary, NC, USA).
Ethics
The study was conducted in accordance with the Helsinki
Declaration of 1975 and was approved by the Clinical Re-
search Ethics Boards at the University of British Columbia
and the BC Cancer Agency.
Results
Baseline demographics for the HCV serological groups
are shown in Table 1. Approximately two thirds of the
HCV positive group, which includes the REAC and
SERO groups, were male. Females were more likely to
be tested than males (55% vs. 45%) and females were
tested more frequently. The REAC group was older than
the SERO group (mean ages 43.4 and 34.1, respectively).
The SMRs for all cause and disease specific mortality
are shown in Tables 2 and 3. All serological groups had
significantly higher all cause mortality than the BC
population, with the highest SMR in the SERO group,
followed by the REAC, MNR and SNR groups. The SMR
for liver related mortality was highest in the REAC
group, followed by the SERO group, whereas the reverse
was true for drug related mortality. In addition, the SMR
for mortality due to mental and behavioural disorders
was highest in the SERO group (Table 3).
Hazard ratios comparing the mortality risk between
the HCV serological groups are shown in Table 4 (and
Additional file 1: Tables S1–S2). With respect to all
cause mortality, the MNR, REAC and SERO groups had
significantly higher mortality risk compared to the SNR
group, particularly for younger individuals. The risk of
liver related mortality was about ten times higher
(HR=9.62; 95% CI=8.55-10.87) for the REAC group vs.Table 1 Baseline demographics for HCV serological groups
Serological group1 SNR
n (all) 375,752
n (12 month lagging)2 342,325
Person years 1,132,262
Mean age at entry (SD) 41.6 (17.04)
Male (%) 150,178 (44%) 31
n deaths (%) 12,777 (3.7%) 2
Data sources: BCCDC Public Health Microbiology and Reference Laboratory, BC Ministr
SNR=single non-reactive; MNR=multiple non-reactive; REAC=reactive at first test; SE
1The serological groups are not mutually exclusive, i.e., over time an individual may
2The N for 12 month lagging accounts for removal of those subjects who were not
first anti-HCV test. Those subjects excluded by 12 month lagging did not form partthe SNR group and about five times higher (HR=5.10;
95% CI=2.30-9.62) for the SERO vs. SNR group. The
SERO group had about one half the liver related mortality
risk of the REAC group (HR=0.53; 95% CI=0.24-0.99).
Drug related mortality risk was significantly higher for
both HCV positive groups vs. the SNR group (SERO:
HR=20.83; 95% CI=15.15-28.57; REAC: HR=13.70; 95%
CI=11.76-16.13). Drug related mortality risk was also
significantly higher for the SERO vs. REAC groups
(HR=1.54; 95% CI=1.12-2.05). The risk of death from
human immunodeficiency virus (HIV) infection was sig-
nificantly higher in both the REAC and SERO groups
vs. SNR, particularly for females. However, the risk of
death from HIV infection was not significantly different
for the SERO vs. REAC comparison (females: HR=0.64;
95% CI=0.16-1.75; males: HR=0.90; 95% CI=0.44-1.63).
Discussion
This study examined all cause and disease specific mor-
tality among individuals tested for HCV antibody in BC
from 1992 to 2004. A unique feature of the study was
the use of a population based central laboratory database
to identify HCV-tested individuals (both positive and
negative results) and to correlate the risk of death with
serological results and testing patterns. To our know-
ledge this is the first study to use time dependent HCV
serological groups to help stratify infection status and
mortality risks. While the risk of death among all in-
dividuals who underwent HCV antibody testing was sig-
nificantly higher than the BC population, the serological
groupings helped to differentiate mortality which was
likely related to risk activities associated with HCV acqui-
sition from mortality associated with HCV related chronic
liver disease.
Our findings confirm that mortality among serocon-
verters was more likely to be drug related. This is con-
sistent with other published studies which demonstrated
no increase in liver related mortality among serocon-
verters during the first decade after infection [27,28],




40.6 (15.01) 43.4 (11.48) 34.1 (9.67)
,457 (43%) 17,780 (64%) 1,332 (55%)
,664 (3.6%) 2,705 (9.7%) 119 (4.9%)
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RO=seroconverter.
fall into more than one group.
followed for a minimum of 12 months or who died within 12 months of their
of the standardized mortality and hazard ratio analyses.
Table 2 Standardized mortality ratios for HCV serological groups vs. BC population
SNR (n=342,325) MNR (n=73,476) REAC (n=27,812) SERO (n=2,408) All HCV +ve (n=30,220)
ICD-10 Cause of death SMR (95% CI) SMR (95% CI) SMR (95% CI) SMR (95% CI) SMR (95% CI)
A00-R99; V01-Y98 All 1.44 (1.41 - 1.46) 2.59 (2.49 - 2.69) 4.68 (4.50 - 4.86) 10.13 (8.39 - 12.12) 4.78 (4.61 - 4.96)
B15-B19; B942; C22; K70-K76 Liver related 3.00 (2.77 - 3.24) 8.44 (7.47 - 9.50) 23.93 (22.03 - 25.95) 14.77 (6.36 - 29.09) 23.73 (21.86 - 25.72)
B15-B19; B942 Viral hepatitis 1.04 (0.70 - 1.49) 2.12 (1.06 - 3.79) 65.32 (58.51 - 72.70) 40.31 (13.06 - 93.93) 64.73 (58.03 - 71.99)
C22 Liver cancer 2.64 (2.26 - 3.07) 4.79 (3.46 - 6.48) 17.31 (14.10 - 21.04) 9.02 (0.23 - 50.23) 17.16 (13.99 - 20.83)
K70-K76 Liver disease 3.68 (3.34 - 4.05) 11.96 (10.43 - 13.65) 11.09 (9.38 - 13.01) 6.52 (0.79 - 23.53) 10.99 (9.31 - 12.88)
K70 Alcoholic 3.64 (3.15 - 4.20) 8.25 (6.50 - 10.33) 10.58 (8.39 - 13.17) 5.45 (0.14 - 30.37) 10.46 (8.30 - 13.00)
K71-K76 Non-alcoholic 3.71 (3.25 - 4.21) 15.65 (13.20 - 18.43) 11.69 (9.11 - 14.77) 8.05 (0.20 - 44.85) 11.62 (9.07 - 14.66)
F11-F16; F19; X40-X44; X60-X64; X85; Y10-Y14 Drug related 1.77 (1.56 - 2.00) 4.54 (3.80 - 5.37) 19.94 (18.31 - 21.69) 36.66 (27.12 - 48.46) 20.72 (19.09 - 22.45)
B20-B24 HIV 1.89 (1.48 - 2.37) 4.08 (2.81 - 5.73) 26.70 (23.49 - 30.22) 35.61 (18.94 - 60.89) 27.03 (23.86 - 30.50)
E10-E14 Diabetes 1.86 (1.69 - 2.03) 5.66 (4.84 - 6.57) 2.21 (1.52 - 3.10) 4.49 (0.11 - 24.99) 2.24 (1.55 - 3.13)
N17-N19; I12-I13; N00-N08 Renal failure 2.41 (2.16 - 2.69) 12.96 (11.12 - 15.03) 4.58 (3.07 - 6.59) 14.85 (0.38 - 82.72) 4.69 (3.16 - 6.70)
C00-C97 Malignant neoplasm 1.34 (1.30 - 1.39) 1.71 (1.57 - 1.86) 2.35 (2.13 - 2.59) 2.03 (0.74 - 4.42) 2.34 (2.12 - 2.58)
C22.0; C22.2-C22.9 Hepatocellular carcinoma 5.34 (4.47 - 6.34) 9.58 (6.67 - 13.32) 36.68 (29.85 - 44.62) 17.04 (0.43 - 94.89) 36.27 (29.54 - 44.07)
Data sources: BCCDC Public Health Microbiology and Reference Laboratory, BC Ministry of Health Services, and BC Vital Statistics Agency.



















Table 3 Disease specific standardized mortality ratios for HCV serological groups vs. BC population
SNR (n=342,325) MNR (n=73,476) REAC (n=27,812) SERO (n=2,408) All HCV +ve (n=30,220)
ICD-10 Cause of death SMR (95% CI) SMR (95% CI) SMR (95% CI) SMR (95% CI) SMR (95% CI)
A00-B99 Infection 1.57 (1.38 - 1.78) 4.36 (3.55 - 5.30) 31.51 (29.08 - 34.09) 32.09 (19.32 - 50.05) 31.53 (29.14 - 34.07)
C00-D48 Neoplasms 1.35 (1.31 - 1.40) 1.72 (1.59 - 1.87) 2.35 (2.14 - 2.59) 1.98 (0.73 - 4.31) 2.35 (2.13 - 2.58)
D50-D89 Blood/immune 1.82 (1.33 - 2.43) 5.18 (2.83 - 8.71) 7.91 (4.09 - 13.84) 36.40 (0.92 - 202.75) 8.41 (4.48 - 14.39)
E00-E90 Endocrine 1.82 (1.67 - 1.97) 5.29 (4.58 - 6.07) 2.07 (1.48 - 2.82) 3.21 (0.08 - 17.87) 2.09 (1.50 - 2.83)
F00-F99 Mental and behavioural 1.16 (1.02 - 1.31) 2.61 (1.99 - 3.37) 6.79 (5.43 - 8.37) 16.01 (4.35 - 40.98) 6.96 (5.60 - 8.55)
G00-G99 Nervous system 1.05 (0.95 - 1.17) 1.49 (1.11 - 1.95) 1.78 (1.21 - 2.53) 6.96 (0.84 - 25.11) 1.87 (1.29 - 2.62)
I00-I99 Circulatory system 1.42 (1.38 - 1.46) 2.22 (2.06 - 2.40) 2.21 (1.98 - 2.45) 6.04 (3.01 - 10.81) 2.25 (2.03 - 2.50)
J00-J99 Respiratory system 1.29 (1.22 - 1.37) 1.70 (1.44 - 1.99) 2.96 (2.46 - 3.53) 5.36 (0.65 - 19.36) 2.98 (2.48 - 3.55)
K00-K93 Digestive system 2.36 (2.20 - 2.53) 7.40 (6.60 - 8.27) 7.97 (6.91 - 9.14) 10.26 (3.33 - 23.92) 8.01 (6.96 - 9.17)
N00-N99 Genitourinary system 1.95 (1.74 - 2.17) 10.47 (8.96 - 12.16) 4.54 (3.14 - 6.34) 12.21 (0.31 - 68.02) 4.62 (3.22 - 6.42)
R00-R99 Other 0.92 (0.68 - 1.22) 3.48 (2.25 - 5.15) 7.43 (5.15 - 10.39) 21.58 (5.87 - 55.24) 7.99 (5.65 - 10.96)
V01-Y98 External 1.44 (1.34 - 1.54) 2.64 (2.34 - 2.98) 8.58 (7.96 - 9.22) 15.25 (11.72 - 19.51) 8.88 (8.28 - 9.52)
Data sources: BCCDC Public Health Microbiology and Reference Laboratory, BC Ministry of Health Services, and BC Vital Statistics Agency.



















Table 4 Hazard ratios between HCV serological groups
MNR vs. SNR REAC vs. SNR SERO vs. SNR SERO vs. MNR SERO vs. REAC
ICD-10 Cause of Death HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
A00-R99; V01-Y98 All
Age <40 2.07 (1.82-2.36) 7.25 (6.54-8.06) 7.52 (5.85-9.52) 3.62 (2.79-4.65) 1.03 (0.80-1.31)
Age ≥40 1.42 (1.36-1.49) 2.39 (2.27-2.51) 3.36 (2.49-4.41) 2.36 (1.75-3.11) 1.41 (1.04-1.85)
B15-B19; B942; C22; K70-K76 Liver related 2.72 (2.34-3.14) 9.62 (8.55-10.87) 5.10 (2.30-9.62) 1.88 (0.85-3.55) 0.53 (0.24-0.99)
F11-F16; F19; X40-X44; X60-X64;
X85; Y10-Y14
Drug related 2.62 (2.11-3.25) 13.70 (11.76-16.13) 20.83 (15.15-28.57) 8.00 (5.71-11.11) 1.54 (1.12-2.05)
B20-B24 HIV related
Female 3.03 (0.90-9.52) 83.33 (40.00-200.00) 52.63 (11.49-200.00) 17.54 (3.62-71.43) 0.64 (0.16-1.75)
Male 1.77 (1.11-2.74) 12.05 (9.09-16.13) 10.87 (5.24-20.41) 6.17 (2.84-12.35) 0.90 (0.44-1.63)
Data sources: BCCDC Public Health Microbiology and Reference Laboratory, BC Ministry of Health Services, and BC Vital Statistics Agency.
MNR=multiple non-reactive; SNR=single non-reactive; REAC=reactive at first test; SERO=seroconverter; HR=hazard ratio.
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acute HCV infection rarely results in fulminant liver
failure [4], and decades are required to develop cirrhosis
[6]. In contrast, individuals whose first anti-HCV test
was reactive were more likely to have chronic HCV in-
fection and had higher risk of liver related mortality,
partly as a result of being older and having survived
their substance use. Drug use was also an important mor-
tality contributor in the REAC group, and in addition,
both the REAC and SERO groups had increased HIV re-
lated mortality.
While it could be argued that the designation of SNR,
MNR, REAC and SERO groups is arbitrary, the grouping
assumptions are supported by the data. The SERO group
was the best characterized group because the date of a
previous negative anti-HCV test was known. The REAC
group was likely heterogeneous and included persons
who may have been infected in the past from contami-
nated blood products, past or present IDU or other risk
factors [29]. The lack of previous serology prevents their
identification as a seroconverter. Persons in the REAC
group had the highest liver related death rate. However,
it is recognized that about 25% of HCV-infected individ-
uals will spontaneously clear infection and remain anti-
body reactive [4] and such individuals are not known to
be at increased risk of HCV related liver disease [30]. In
contrast, seronegative individuals who tested only once
likely had some baseline risks which led to serological
testing. Therefore, the SNR group represents a relatively
conservative comparator group given that their mortality
risks were only slightly higher than the general BC
population. Multiple negative testers likely had ongoing
risks. For example, they were more likely to die of renal
failure, diabetes and both alcoholic and non-alcoholic
liver disease.
Our results are consistent with other population based
studies, summarized in Table 5, from Australia [12],
Sweden [13] and Scotland [15], which reported SMRs17- to 46-fold higher for liver related and 19- to 37-fold
higher for drug related mortality among HCV-infected
persons vs. the general population. As expected, the
mean age of the SERO group was significantly lower
than the REAC group, which likely reflects a larger pro-
portion of younger IDUs in the SERO group. Of note,
83% of individuals in BC who seroconverted within the
previous twelve months and who could be contacted
reported a history of IDU [31].
A recent study in the United States by El-Kamary
et al. [32] utilized data from the National Health and
Nutrition Examination Survey (NHANES) to examine
mortality among HCV-uninfected, HCV antibody posi-
tive/HCV RNA negative, and HCV chronically infected
individuals. This study used mortality rate ratios that
showed all cause mortality among chronically infected
individuals was more than twice that of HCV negative
individuals and that 57.8% of the mortality was attribut-
able to HCV. While our study demonstrated an in-
creased drug related mortality in association with HCV
infection, El-Kamary et al. [32] did not find a significant
association between HCV status and non-liver related
deaths. This may reflect differences in the underlying risk
factors in the populations studied, i.e., the NHANES-
based study reflects a random population sample which
was then tested for HCV, whereas our study involved indi-
viduals who underwent diagnostic HCV testing.
Co-infections with HIV and hepatitis B virus (HBV) are
common in HCV-infected individuals, and co-infected in-
dividuals have increased mortality relative to HCV mono-
infected individuals [12-15]. Although we were unable to
differentiate HCV mono-infected individuals from those
co-infected, the HCV positive group (REAC and SERO
groups combined) would be expected to include HBV and
HIV co-infected individuals. HIV and HCV prevalence
rates among BC IDUs have been reported as 17% [33] and
83% [34] respectively, and among HIV positive individuals
in BC, the HCV co-infection rate has been estimated to be
Table 5 Comparison of standardized mortality ratios with other studies
Author Country All cause SMR (95% CI) Liver related SMR (95% CI) Drug related SMR (95% CI)
Amin [12] (2006) Australia HCV mono-infected 3.1 (3.0-3.2) 16.8 (15.4-18.3) 19.3 (18.1-20.5)
HCV/HBV co-infected 5.6 (4.8-6.6) 32.9 (23.1-46.7) 24.7 (18.2-33.5)
Duberg [13] (2008) Sweden HCV mono-infected 5.8 (5.6-6.0) 35.5 (32.9-38.3) 20.7 (18.9-22.7)
HCV/HBV co-infected 8.5 (7.3-9.8) 46.2 (31.5-62.3) 27.6 (19.6-39.6)
McDonald [15] (2008) Scotland HCV mono-infected 4.9 (4.6-5.1) 20.0 (17.9-22.2) 23.5 (21.3-25.7)
HCV/HIV co-infected 32.9 (29.2-37.0) 34.8 (23.3-50.0) 36.6 (25.2-51.4)
Yu (2012) Canada All HCV-infected 4.8 (4.6-5.0) 23.7 (21.9-25.7) 20.7 (19.1-22.5)
REAC 4.7 (4.5-4.9) 23.9 (22.0-26.0) 19.9 (18.3-21.7)
SERO 10.1 (8.4-12.1) 14.8 (6.4-29.1) 36.7 (27.1-48.5)
SMR=standardized mortality ratio; HCV=hepatitis C virus; HBV=hepatitis B virus; HIV=human immunodeficiency virus; REAC=reactive at first
test; SERO=seroconverter.
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was unknown unless the individual died of HIV related
causes. The SMRs for all cause, liver and drug related
mortality for our HCV positive group were, however, simi-
lar to other HIV co-infected populations [15].
The time dependent Cox proportional hazard model-
ling revealed an 83-fold higher HIV related mortality for
women in the REAC group relative to SNR women,
whereas REAC men displayed a 12-fold higher mortality
relative to SNR men. This may reflect the lack of access
to care by highly marginalized women who are then
more likely to die of HIV related causes.
This study has important public health implications. In
the short term, younger drug users, here represented by
the seroconverters, would likely benefit more from harm
reduction, including needle distribution and methadone
maintenance programs to reduce the risk of drug related
mortality, than from antiviral treatment when their risk of
liver related mortality is low [36]. In contrast, individuals
with chronic HCV infection would benefit from harm
reduction programs and antiviral treatment to reduce the
risk of drug related mortality and progressive liver disease.
These findings are consistent with a recent HCV costing
analysis in BC where substantial HCV related direct
healthcare costs could be ascribed to mental health, addic-
tions and associated risk activities which lead to HCV ac-
quisition, as well as the consequences of progressive liver
disease [21]. Of note, early treatment of IDUs has been
shown to be cost-effective [37]. Since most onward HCV
transmission involves IDU, virological cure could poten-
tially reduce incident HCV infections.
The study has several limitations. Approximately 20% of
individuals in the laboratory dataset had no PHN and
could not be deterministically linked, which could lead to
exclusion of vulnerable individuals, e.g., with no fixed
address, who have been shown to have higher HCV pre-
valence and morbidity/mortality risks compared to the
general population [1]. As with all administrative data
linkages, the ability to control for confounders such asHCV transmission risks, co-morbidities or social deter-
minants of health, which may impact access to testing, is
limited. Misclassification of seroconverters within the
REAC group would occur if a recently infected individual
had no prior HCV test, but the SERO vs. REAC compari-
son was considered a reasonable surrogate for comparing
incident vs. chronic HCV infection. All of these limita-
tions could lead to underestimation of SMR and HR in
our study. Seriously ill individuals or recipients of un-
screened blood products in the past are more likely to be
tested, and our attempt to compensate for potential notifi-
cation bias by applying a twelve month lagging period to
study enrolment may have been insufficient. We did not
analyze HCV RNA results which were available for only a
limited number of individuals. Therefore, individuals who
had cleared their infection would have been classified as
incident or chronic infections based on their anti-HCV
test results. Since individuals who spontaneously clear
their HCV infection are not known to be at risk of pro-
gressive liver disease [30], our SMR and HR estimates for
mortality due to chronic HCV infection, especially for
liver related mortality, are likely conservative. Different
anti-HCV screening tests were used during the study
period (second generation from 1992 to 1997 and third
generation from 1997 to 2004). However, both assays have
good sensitivity and specificity [38] so this is unlikely to
significantly affect diagnostic accuracy. The death register
data are considered reliable as registration is a mandatory
requirement, subject to federal/provincial standards and
coded according to ICD-10 classification. However, since
only 7.1% of all deaths in BC (2009 data) had an autopsy
[39], the listed underlying cause of death may not be com-
pletely reliable. Deaths attributable to viral hepatitis pri-
marily result from chronic liver disease and liver failure,
and viral hepatitis may not consistently be listed as the
underlying cause of death, leading to underestimation of
deaths due to chronic viral hepatitis. In addition, deaths
which occurred outside of BC were not captured in the
analysis.
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cohort design, and longitudinal population based sero-
logical data. The large sample size allowed us to more pre-
cisely measure the effect of mortality attributable to HCV
infection than smaller studies. The longitudinal serological
data with HCV seropositive and seronegative results en-
abled the identification of incident HCV cases and multiple
non-reactive testers. This information helped to differenti-
ate HCV related mortality due to progressive liver disease
from the risk behaviours/activities that are associated with
HCV acquisition.
Conclusions
We found excess mortality due to progressive liver dis-
ease and risk activities related to HCV acquisition
among individuals who test anti-HCV positive. From a
policy perspective, reduction of HCV related mortality
requires comprehensive prevention and harm reduction
programming and improved treatment uptake to reduce
the consequences of chronic HCV infection, which in-
clude progressive liver disease and other extra-hepatic
illnesses.
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